Precis: This study highlights the translational relevancy of patient-derived colorectal cancerxenografts which recapitulate IGF2-PI3K and ERBB-RAS genomic alteration profiles, and cetuximab response observed in patients.
INTRODUCTION
Colorectal cancer (CRC) remains a major cause of mortality worldwide and CRC patient death is generally attributable to metastasis development. Comprehensive molecular characterization of CRC has identified key gene and pathway alterations important for initiation and progression of CRC, including alterations in the PI3K and ERBB-RAS pathways (1, 2) . Some genetic anomalies have been also shown to predict response to specific therapies, such as activating mutations in KRAS which predict resistance to anti-EGFR monoclonal antibodies (MAb) (3) . For efficient development of new therapies and companion biomarkers, preclinical models mimicking the molecular epidemiology and drug sensitivity of human tumors are needed.
In CRC, tumor-specific patient-derived xenograft (PDX) models have shown to retain the intratumoral clonal heterogeneity, chromosomal instability, and histology of the parent tumor through passages in mice (4) (5) (6) (7) . To extend these observations, we investigated here a collection of 52 colorectal PDXs (6) , composed of 48 MSS (microsatellite stability) and 4 MSI (microsatellite instability) tumors, for the presence and prevalence of molecular features reported in large CRC patient cohorts (1, 2, 8) . In particular, we studied key alterations in IGF2-PI3K and ERBB-RAS pathways and the role of these alterations in predicting response to cetuximab.
Research. 
MATERIALS and METHODS
Patient-derived tumor xenografts. Tumor xenografts were established directly from patient tumors (6) and were routinely passaged by subcutaneous engraftment in immunodeficient CB17-SCID mice (Charles River Laboratories). Xenografts, passage P6-P9, were harvested from 3 mice for each model, when they reached around 150-300 mm 3 in size for RNA and DNA extraction. For in vivo pharmacological studies. Cetuximab (Imclone) was given at 12.5 mg/kg/adm, (Q3Dx2)x2 IP), mice bearing 100-200 mm 3 tumors at start of therapy (n = 8-10 per group) as already described (6) . All experimental procedures were approved by Sanofi Laboratory Animal Care and Use committee.
Microsatellite Instability (MSI) status. MSI testing was performed according to the National Cancer Institute guidelines using a five-microsatellite consensus panel (6) .
DNA sequencing. Next-generation sequencing and mutation calling were performed at Beijing Genomics Institute (BGI). Library preparation was performed using exome capture Agilent SureSelect All Exon 50M. Libraries were sequenced using the Illumina HiSeq platform. Quality single-nucleotide polymorphism (SNP) calling criteria have been applied: SNP quality is equal or greater than 20; the minimum sequencing depth is 4X and the mean is 100X, with 99% of coverage target region. To evaluate and eliminate the false positive SNPs calls generated by cross hybridization with mouse DNA, we have detected and filtered out reads aligned to mouse reference sequences before doing human whole-exome sequencing analysis; by this way, only specific human calling are considerate.. Besides, Gene expression profiling. The analysis of gene expression was done using U133 Plus Affymetrix microarrays with biological triplicate (3 tumor tissues removed from 3 distinct mice for each model, passage P6-P9).
KRAS, BRAF
Real-time RT-PCR. Affymetrix data of candidate genes were confirmed by qRT-PCR using previously described methodology (9) . 
RESULTS and DISCUSSION
Comprehensive molecular characterization of tumor samples from CRC patients has identified a handful of recurrent mutated genes within critical pathways (1, 2, 10) . Among these, the PI3K and ERBB-RAS signaling, accurately dissected by the Cancer Genome Atlas Network (TCGA) (2), provide promising therapeutic targets.
In order to gain more insight into the genomic abnormalities within the PI3K and ERBB-RAS signaling pathways, a large cohort of 52 colorectal PDXs established by the CReMEC consortium (6) (48 MSS and 4 MSI tumors) was analyzed.
We first examined 6 genes identified as key upstream elements in the PI3K pathway However, overexpression of IRS2 (n=5) was detected in mutually exclusive pattern with IGF2 amplification or overexpression ( Figure 1A) . All PI3KCA aberrations (n=12) were oncogenic mutations, affecting all functional domains of the enzyme but with preferential mutation hotspots within exons 9 and 20, as previously described in CRC (13) . PIK3R1 mutations have been rarely reported in CRC (2) and none were detected in the present PDX collection. Finally, we observed no significant association of alterations in the RAS and PI3K pathways, suggesting that simultaneous inhibition of the RAS and PI3K pathways might be necessary for successful therapy in the subgroup displaying co-occurrence of these molecular alterations.
These genomic analyses enable an assessment of the diversity and the frequency of genomic changes altering these two major signaling pathways in our CRC PDX models and comparison with TCGA data (Figure 2) . TCGA has reported that 77% (23/30) of hypermutated tumors are MSI tumors (2) . As the present PDX collection displays a low In addition to maintaining the genomic and histological heterogeneity, translationallyrelevant preclinical models need to reproduce drug response observed in patients. While KRAS mutations had been identified as a strong predictive biomarker of resistance to cetuximab and panitumumab (3), only a subset of KRAS wild-type (WT) patients respond to anti-EGFR MAbs, underlining that additional predictive biomarkers exist within KRAS WT tumors. The characterization of alterations occurring in additional candidate genes (NRAS, BRAF, PIK3CA, PTEN) increased indeed the negative predictive value up to 70%, but it is not sufficient to identify all resistant cases (19) .
To assess drug response prediction in our PDX models, cetuximab response was analysed in the PDX panel. To be consistent with clinical criteria, we considered responders the PDXs displaying partial or complete response and non-responders the PDXs displaying growth stabilization or progression (Supplementary Figure 2) . With these scoring criteria, 8 out of 52 PDXs (15%) were responders to cetuximab, with complete tumor disappearance in 3 PDX models. The all 8 responders were WT KRAS tumors (Figures 1A and 3) , outlining the requirement of WT KRAS genotype for clinical benefit. This low proportion of PDX responders in an unselected population (15%) is highly concordant with patient data (8) and PDX data from an independent metastatic colorectal cancer xenograft series (7). Noteworthy, cetuximab had been shown to be active against KRAS mutated xenografts (6) CAN-14-1590 mutation assessment to codons 12-13, KRAS codon 61 and 146 mutations, in addition to NRAS and BRAF mutations, have also been shown in retrospective studies to predict resistance to cetuximab or panitumumab in WT KRAS codon 12 and 13 metastatic CRC (19, 20) . The European Medicines Agency recently updates and restricts the indication for cetuximab to WT RAS metastatic colorectal cancer (not only WT KRAS codon 12-13).
Likewise, none of the 4 BRAF V600E-mutated, 6 NRAS-mutated and 4 KRAS (codon 61, 117 or 146) mutated PDXs responded to cetuximab with tumor shrinkage. Therefore, exclusion of these mutations enables an improved selection of PDXs likely to respond to cetuximab, increasing the response rate from 28% (8 out of 29 12-13 codons KRAS WT) to 53% (8/15) in PDXs that are fully wild-type for all three genes, as reported retrospectively in patients (19, 20) . This study functionally cross validates a recent clinical stratification based on combination of predictive biomarkers obtained retrospectively in patients (19) . These data support the utility of our PDX panel for identifying predictors of drug response in metastatic colorectal cancer patients.
As for PTEN and PIK3CA impact, clinical data are more conflicting (8, 13, 19) . In the present preclinical work, only PTEN homozygous deletion, leading to absolute PTEN inactivation, has been taken into account. This PTEN loss occurred within KRAS mutated xenografts, displaying lack of response to cetuximab. Individual contribution of PIK3CA mutations to the absence of response is difficult to assess because of the PIK3CA mutation diversity in different protein domains and coexistence of these mutations with KRAS and BRAF mutations (13) . Moreover, 1 PDX with IGF2 activation and 2 others PDXs with PIK3CA mutation respond to cetuximab. Among the 5 IGF2-overexpressed KRAS WT tumors, only one responds to cetuximab. Taken together, these data suggest that IGF2-PI3K components are not biomarkers of resistance to anti-EGFR therapies and underline the interest to Table 1 ). Noteworthy, none of the patients with colorectal cancer, from whom the triple wild-type PDXs were derived, had been exposed to anti-EGFR therapy prior to surgery, ruling out the possibility of acquired resistance in the pre-treated PDXs. The analysis of these parameters did not allow to statistically discriminating between the responder and non-responder groups (Fisher's exact test, p>0.05). Nevertheless, it is noteworthy that cetuximab treatment was ineffective in mice engrafted with the 3 PDX models carrying KRAS amplification.
Collectively, the present data demonstrate the relevance of colorectal PDXs as models for preclinical drug development. The PDX models remarkably fit the molecular epidemiology and the cetuximab drug response profiles of CRC patient populations, justifying the growing use of mouse clinical trials in cancer drug development and decision making (5).
More importantly, these data support the identification of KRAS (exon 2, 3 and 4) / NRAS / BRAF wild-type patients for treatment with cetuximab, and IGF2 as an attractive novel cancer drug target in a large subset of CRC patients.
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